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KEY POINTS  
 
• Eleven pedigrees were identified with biallelic pathogenic variants in RASGPR2, 
which encodes platelet CalDAG-GEFI 
 
• CalDAG-GEFI deficiency is a severe, recessive, non-syndromic platelet function 
disorder with defective aggregation to multiple agonists 
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ABSTRACT  
Heritable platelet function disorders (PFDs) are genetically heterogeneous and 
poorly characterised. Pathogenic variants in RASGRP2, which encodes calcium and 
diacylglycerol-regulated guanine exchange factor I (CalDAG-GEFI), have been 
reported previously in three pedigrees with bleeding and reduced platelet 
aggregation responses. To better define the phenotype associated with pathogenic 
RASGRP2 variants, we compared high-throughput sequencing and phenotype data 
from 2,042 cases in pedigrees with unexplained bleeding or platelet disorders to data 
from 5,422 controls. Eleven cases harboured 11 different, previously unreported 
RASGRP2 variants that were biallelic and likely pathogenic. The variants included 
five high-impact variants predicted to prevent CalDAG-GEFI expression and six 
missense variants affecting the CalDAG-GEFI CDC25 domain, which mediates Rap1 
activation during platelet inside-out αIIbβ3 signalling. Cases with biallelic RASGRP2 
variants had abnormal mucocutaneous, surgical and dental bleeding from childhood, 
requiring at least one blood or platelet transfusion in 78% of cases. Platelets 
displayed reduced aggregation in response to ADP and epinephrine, but variable 
aggregation defects with other agonists. There were no other consistent clinical or 
laboratory features. These data enable definition of human CalDAG-GEFI deficiency 
as a non-syndromic, recessive PFD associated with a moderate or severe bleeding 
phenotype and complex defects in platelet aggregation. 
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INTRODUCTION  
Heritable platelet function disorders (PFD) are genetically heterogeneous rare 
diseases characterised by mucocutaneous, surgical and traumatic bleeding1,2 and 
reduced platelet responses to activating agonists.3,4 Human PFD have been 
associated with causal variants in more than 30 genes, often associated with 
distinctive clinical or laboratory phenotypes that inform selection of candidate genes 
for diagnosis.5 Several new PFD with less distinctive phenotypes have recently been 
identified using high-throughput sequencing.6-8 However, to date these have only 
been reported in small numbers of pedigrees and are incompletely characterised.  
 
One such example is the PFD associated with loss-of-function variants in 
RASGRP2, which encodes calcium and diacylglycerol-regulated guanine exchange 
factor I (CalDAG-GEFI). This PFD was first identified in a consanguineous pedigree 
with a homozygous p.G248W variant associated with bleeding and reduced platelet 
light transmission aggregation (LTA) responses to multiple agonists.9 CalDAG-GEFI 
deficiency has been reported subsequently in only three pedigrees worldwide.10,11  
 
In order to better define the phenotype and mutational spectrum of CalDAG-GEFI 
deficiency, we analysed data from a collection of 2,042 cases with unexplained 
bleeding or platelet disorders (BPD) to identify 11 new affected pedigrees. 
 
METHODS 
RASGRP2 was investigated in two study collections in which all participants were 
enrolled to the National Institute for Health Research BioResource - Rare Diseases 
between 2012 and 2016 after providing informed written consent (UK Research 
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Ethics Committee approval 13/EE/0325). The first collection comprised 1,472 cases 
or pedigree members with unexplained BPD and 5,422 cases with other rare 
inherited disorders who underwent whole exome or genome sequencing.12 The 
second collection comprised 570 other BPD cases analysed using the 
ThromboGenomics high-throughput platform13, which captures variants in 81 tier one 
genes for BPD, designated by the ISTH Genomics Scientific and Standardisation 
Subcommittee. 
 
Collection of clinical and laboratory phenotypes and coding with Human Phenotype 
Ontology (HPO) terms were performed as previously described.12 Variants from 
high-throughput sequencing were obtained using Isaac (Illumina, Inc.; San Diego, 
CA) or as described previously.12 Variants were not considered to be potentially 
pathogenic if the Variant Effect Predictor14 identified them as synonymous relative to 
canonical transcript ENST00000354024, or if the allele frequency was greater than 
1/1000 in reference databases.12,15 Index cases in the NIHR BioResource were 
classified as having an indicator phenotype of CalDAG-GEFI deficiency if they had 
HPO terms indicating abnormal bleeding and reduced LTA responses to at least 
three agonists. Associations between rare and non-synonymous RASGRP2 variants 
in the NIHR BioResource and the presence or absence of the indicator phenotype 
were then assessed using the BeviMed method.16  
 
RESULTS AND DISCUSSION 
The CalDAG-GEFI deficiency indicator phenotype of bleeding and reduced LTA 
responses to at least three agonists was present in 119 (9.7%) of 1,229 BPD index 
cases from the NIHR BioResource. Analysis of all the rare, non-synonymous 
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variants in the BPD and non-BPD index cases revealed a strong statistical 
association between the indicator phenotype and the presence of at least two 
RASGRP2 alleles, obtaining a posterior probability of association with recessive 
inheritance of 1 by inference using the BeviMed method (Figure 1A). The 
association was driven by eight different variants observed in eight BPD index cases 
as homozygous or compound heterozygous alleles (Figure 1B; pedigrees A-H in 
Figure 2A). There were a further 35 RASGRP2 variants which were not associated 
with the indicator phenotype or which were present as a single allele (Figure 1A). In 
the ThromboGenomics collection, there were four rare, non-synonymous RASGRP2 
variants that were biallelic (Figure 1B) in 3 index cases with bleeding and reduced 
LTA responses to at least three agonists (pedigrees I-K in Figure 2A). Since this 
analysis, pedigree G has also been reported elsewhere.17 
 
Of the 11 likely pathogenic RASGRP2 variants, four resulted in frameshift or a stop 
codon when annotated against the RASGRP2 canonical transcript (Figure 1B, 1C). 
One further variant (11:64507638 G>C: pedigree K) was at the -3 position in the 
intron 5 splice region, adjacent to the splice acceptor site.  The Alamut® Visual 
splicing module (Interactive Biosoftware, Rouen, France) predicted this to result in 
loss of the native splice acceptor site and co-option of a cryptic acceptor site in exon 
6, leading to deletion of nine codons and a stop gain at codon 125 (Figure 1C). 
Thus, a total of five variants were predicted to prevent full length CalDAG-GEFI 
expression. 
 
All six missense variants predicted substitutions of amino acids that were conserved 
in CalDAG-GEFI orthologs in nine distantly related species, except for human 
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residue A345 that is a T residue in the Xenopus ortholog (Figure 1B and 
Supplementary table S1). All had high CADD pathogenicity scores (>20; within the 
top 1% of deleterious variants genome-wide)18 and were either absent or at very low 
allele frequency in the ExAC population database (Figure 1B).15 All the predicted 
substitutions were in the CDC25 domain of CalDAG-GEFI that is essential for 
guanine nucleotide exchange activity, and directly interacts with Rap1, the major 
platelet target for CalDAG-GEFI in the inside-out αIIbβ3 signalling pathway.19 This 
suggests that the missense variants reduce platelet function by altering CalDAG-
GEFI function, although we cannot exclude reduced protein expression, as observed 
previously for the RASGRP2 p.Ser381Phe variant.11 There were no consistent 
phenotype differences between the cases with missense and high-impact variants.  
 
The 11 likely pathogenic RASGRP2 variants occurred in a total of 11 unrelated 
cases (7 males) as homozygous (7 cases) or compound heterozygous (4 cases) 
alleles, indicating autosomal recessive inheritance. One pedigree (J) contained a 
sibling with biallelic RASGRP2 variants (Figure 2A). All the index cases had a first 
diagnosis of a bleeding disorder during childhood (age 1-14 years; Supplementary 
table S2). Abnormal bleeding was predominantly mucocutaneous or followed 
surgery or dental extraction. Gastrointestinal bleeding occurred in two cases (Figure 
2B), but there was no intracranial bleeding.  Of the nine index cases with available 
data, seven had required red cell or platelet transfusion on at least one occasion 
suggesting severe bleeding. There were no other consistently reported phenotypes. 
Platelet number and size were normal (Supplementary table S2). 
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All 11 index cases had reduced platelet LTA responses with ADP and epinephrine, 
and in some cases also with collagen, arachidonic acid and TRAP-6 (Figure 2C, 
2D). Detailed analysis of A-II3 and B-II1 showed additionally that the velocity of 
aggregation to all tested doses of ADP, epinephrine and TRAP-6 was reduced 
compared with controls (Figure 2D). The normal platelet ultrastructure, nucleotide 
content and release of alpha (P-selectin exposure) and dense (CD63 exposure) 
granules in response to high dose TRAP14 indicated no defect in platelet granule 
biosynthesis. However, dense granule release with ADP was diminished in most 
tested cases, mirroring the functional defects observed with LTA (Supplementary 
table S2), similar to previous reports. 9,10,11  
 
This report of 11 new pedigrees significantly expands the reported cases with human 
CalDAG-GEFI deficiency and enables description of this disorder as an autosomal 
recessive, non-syndromic PFD that is associated with moderate or severe bleeding, 
similar to other disorders of αIIbβ3 integrin signalling20,21 and some types of 
Glanzmann thrombasthenia in which there is reduced expression of functional αIIbβ3 
integrin.22 We show further that there is a consistent laboratory phenotype of 
reduced aggregation responses to ADP and epinephrine in all reported cases, but no 
defect in dense granule secretion, distinguishing this disorder from δ-storage pool 
disease. This distinctive phenotype is likely to assist genetic diagnosis of further 
pedigrees. 
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FIGURE LEGENDS 
Figure 1. Identification and characteristics of pathogenic variants in RASGRP2 
A. BeviMed inference analysis applied to rare, non-synonymous RASGRP2 variants 
observed in all index cases from the NIHR BioResource. Cases were designated as 
having the indicator phenotype of CalDAG-GEFI deficiency if they had HPO terms 
indicating bleeding and reduced light transmission aggregation responses to at least 
three activating agonists. The indicator phenotype was present in 119 index cases 
and was absent in 5,982 index cases. The posterior probability of the association 
model was 1 (prior was 0.1) and the posterior probability of recessive inheritance 
was 1 (prior was 0.5). The RASGRP2 exons are represented by grey blocks. The bar 
chart above shows the marginal posterior probabilities of pathogenicity for individual 
variants observed in all NIHR BioResource index cases, conditional on an 
association under a recessive mode of inheritance. The bar chart beneath indicates 
whether the variant was observed in an index case with (pink) or without (blue) the 
indicator phenotype and whether present as a heterozygous and homozygous allele. 
Variants observed in index cases as compound heterozygous alleles are linked. B. 
The characteristics of the 11 likely pathogenic RASGRP2 variants across the NIHR 
BioResource (NBR) and ThromboGenomics (TG) collections. Variants were 
annotated against the canonical transcript ENST00000354024 using the Variant 
Effect Predictor (VEP).14 Population allelic frequencies are derived from the Exome 
Aggregation Consortium (ExAC) 15. The likely pathogenicity of the variants is 
expressed as the Combined Annotation Dependent Depletion (CADD) score18 and 
the percentage conservation as the proportion of CalDAG-GEFI orthologs in nine 
species that have the same amino acid as human CalDAG-GEFI. C. Localization 
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and predicted consequence of the likely pathogenic RASGRP2 variants identified in 
NIHR BioResource and ThromboGenomics collections (below protein diagram) and 
the previously reported variants 9-11 (above protein diagram). The exploded view 
shows the predicted consequence of the 11:64507638 G>C variant identified as a 
homozygous allele in case in ThromboGenomics case K II.1. Bioinformatic analysis 
of the variant sequence predicts preferential use of an alternative exonic splice 
acceptor, resulting in codon deletion, frameshift and a stop gain at codon 125.  
 
 
Figure 2: Characteristics of the 11 index cases with likely pathogenic biallelic 
RASGRP2 variants.  
A. Pedigrees of the index cases (*) with likely pathogenic RASGRP2 variants 
indicating the genotype of the index cases. The black symbols indicate cases with 
abnormal bleeding and reduced platelet aggregation responses. The white symbols 
indicate pedigree members without bleeding symptoms and the grey symbols, 
pedigree members unavailable for evaluation. +/V: heterozygous, V/V: compound 
heterozygous or homozygous for the variant allele.  B. Annotation of 11 index cases 
with HPO terms for bleeding symptoms. C. Summary light transmission aggregation 
for all 11 index cases. Data are expressed as the proportion of index cases with any 
reported defect in aggregation responses to ADP, epinephrine (Epi), collagen (Coll), 
arachidonic acid (AA), TRAP-6 and ristocetin (Risto). D. Detailed light transmission 
aggregation response in cases AII-3 and BII-1 in response to the stated agonist 
concentrations. Data are presented as the maximum aggregation and initial velocity 
of the aggregation responses.  
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